Three-drug combination for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with advanced liver cancer (hepatocellular carcinoma) that has spread, cannot be removed with surgery, or has not responded to local treatments like chemoembolization or ablation.
- You must be 19 years old or older.
- You should be generally active and able to take care of yourself (ECOG performance status 0 or 1).
- Your liver function should be relatively good (Child-Pugh class A).
- You must not have had any previous whole-body cancer treatment for liver cancer, such as chemotherapy, immunotherapy, or targeted pills.
- Your hepatitis B or C status must be stable and controlled, with appropriate treatment if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (TPST-1120, atezolizumab, and bevacizumab) for people with advanced liver cancer that hasn't been treated before. The goal is to see if adding this new drug to the standard immunotherapy and targeted therapy helps shrink or control the cancer better.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.